



Interface Prescribing & New Therapies Subgroup



Date of original recommendation: 24th March 2009
Dates Re-reviewed: 20th April 2010 and 25th September 2012.

Co-Careldopa (Duodopa®▼) Intestinal Gel for the treatment for advanced Parkinson's disease

The New Therapies Subgroup discussed the above drug at a meeting on the 25th September 2012. The recommendation of this subgroup is as follows:*

The New Therapies Subgroup of the GMMMG considered the use of Duodopa® intestinal gel for the treatment of advanced Parkinson's disease.

The group does not recommend the use of Duodopa® intestinal gel

The group noted that there was limited evidence of benefit with regards long term clinical and cost effectiveness.

According to set criteria duodopa was deemed to be a low priority for funding.

Please note that as of April 2013 this recommendation will be superseded by national policy

Review date: September 2014.

* Unless superseded by NICE guidance or substantial and significant new evidence becomes available.

▼ Newly marketed drugs and vaccines are intensively monitored for a minimum of two years, in order to confirm the risk / benefit profile of the product. Healthcare professionals are encouraged to report all suspected adverse drug reactions regardless of the severity of the reaction.